Concord Biotech Limited (NSE:CONCORDBIO)

Concord Biotech Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	190.42	9.05	151.42	34.99	6.67	51.44
Short-Term Investments	3,123	179.89	228.22	305.8	872.5	550
Trading Asset Securities	-	3,165	2,437	1,369	734.73	1,410
Cash & Short-Term Investments	3,314	3,354	2,817	1,710	1,614	2,011
Cash Growth	16.78%	19.09%	64.71%	5.96%	-19.76%	0.31%
Accounts Receivable	3,968	5,217	3,496	2,738	2,322	1,775
Other Receivables	-	210.46	193.66	217.95	272.74	358.19
Receivables	3,968	5,427	3,690	2,956	2,594	2,133
Inventory	2,763	2,397	2,080	2,123	1,951	1,536
Prepaid Expenses	-	73.91	73.31	55.19	47.61	45.44
Other Current Assets	754.16	100.48	303.06	433.05	119.5	345.27
Total Current Assets	10,798	11,352	8,962	7,277	6,327	6,071
Property, Plant & Equipment	8,623	8,442	7,865	7,655	6,436	5,577
Long-Term Investments	450.77	227.81	20.7	79.25	2.56	3.66
Other Intangible Assets	15.81	11.22	3.2	1.98	35.77	64.18
Other Long-Term Assets	340.53	308.86	156.1	126.8	327.4	108.69
Total Assets	20,232	20,343	17,007	15,140	13,128	11,825
Accounts Payable	865.85	1,130	944.35	938	831.06	463.97
Accrued Expenses	-	192.07	168.21	146.19	131.45	102.38
Short-Term Debt	-	3.81	-	-	43.37	50.99
Current Portion of Long-Term Debt	-	-	62.3	250	250	250
Current Portion of Leases	10.42	19.58	16.21	1.47	15.96	13.01
Current Income Taxes Payable	4.4	101.27	54.94	89.99	-	-
Current Unearned Revenue	-	-	-	13.13	32.72	-
Other Current Liabilities	669.16	393.5	175.55	479.67	247.1	177.04
Total Current Liabilities	1,550	1,841	1,422	1,918	1,552	1,057
Long-Term Debt	-	-	-	62.36	312.49	562.5
Long-Term Leases	5.65	6.3	18.87	1.64	3.11	16.33
Long-Term Deferred Tax Liabilities	384.03	340.22	280.65	234.39	209.71	174.53
Other Long-Term Liabilities	24.58	28.2	19.56	22.97	18.74	20.98
Total Liabilities	1,964	2,215	1,741	2,240	2,096	1,832
Common Stock	104.62	104.62	104.62	104.62	95.11	95.11
Additional Paid-In Capital	-	819.71	819.71	819.71	829.22	829.22
Retained Earnings	-	17,203	14,342	11,976	10,108	9,069
Shareholders' Equity	18,268	18,127	15,266	12,900	11,032	9,994
Total Liabilities & Equity	20,232	20,343	17,007	15,140	13,128	11,825
Total Debt	16.07	29.69	97.38	315.46	624.93	892.83
Net Cash (Debt)	3,298	3,325	2,719	1,395	988.98	1,118
Net Cash Growth	17.64%	22.26%	94.98%	41.02%	-11.58%	-24.66%
Net Cash Per Share	31.44	31.78	25.99	13.33	9.45	10.69
Filing Date Shares Outstanding	105.44	104.62	104.62	104.62	104.62	104.62
Total Common Shares Outstanding	105.44	104.62	104.62	104.62	104.62	104.62
Working Capital	9,249	9,512	7,541	5,359	4,775	5,014
Book Value Per Share	173.32	173.27	145.93	123.31	105.45	95.53
Tangible Book Value	18,255	18,116	15,263	12,898	10,996	9,930
Tangible Book Value Per Share	173.13	173.17	145.90	123.29	105.11	94.91
Land	-	629.93	547.11	547.11	547.11	546.99
Buildings	-	3,553	2,576	2,463	2,226	1,981
Machinery	-	6,622	4,979	4,788	4,285	3,773
Construction In Progress	-	501.31	2,115	1,727	741.55	179.46

Source: S&P Global Market Intelligence. Standard template. Financial Sources.